Online inquiry

IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5447MR)

This product GTTS-WQ5447MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets tcdA gene. The antibody can be applied in Clostridium difficile infectious diarrhea research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq WP_009902072.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 57299391
UniProt ID P16154
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ5447MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5700MR IVTScrip™ mRNA-Anti-CD3E&CEACAM5, CEA TCB(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CEA TCB
GTTS-WQ5705MR IVTScrip™ mRNA-Anti-CD3E&CEACAM5, CEA TCB(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CEA TCB
GTTS-WQ4086MR IVTScrip™ mRNA-Anti-IGF, BI 836(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BI 836
GTTS-WQ14147MR IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA aIL6R88
GTTS-WQ641MR IVTScrip™ mRNA-Anti-AOC3, 8c10(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 8c10
GTTS-WQ9734MR IVTScrip™ mRNA-Anti-TFRC, JR-141(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA JR-141
GTTS-WQ965MR IVTScrip™ mRNA-Anti-CD40, ABBV-323(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABBV-323
GTTS-WQ14363MR IVTScrip™ mRNA-Anti-TNF, r-hTBP-1(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA r-hTBP-1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW